These findings, together with high expression of GATAD2B in breast cancer patients that are non-responsive to chemotherapy, suggests the potential of GATAD2B to serve as a clinical prognosis marker for breast cancer patients. The gene discussed is GATAD2B; the disease is breast carcinoma.